15-year effects of initiating treatment for Parkinson’s disease with dopamine agonists or monoamine oxidase B inhibitors compared with levodopa: final results of PD MED early disease randomisation
Objective: PD MED EARLY is a large, pragmatic trial aiming to determine which class of drug as initial treatment provides the most effective long-term control…A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson’s disease dementia.
Objective: To evaluate the safety and tolerability of repurposing Ambroxol as a disease modifying treatment for Parkinson’s Disease Dementia (PDD). Background: Carrying a mutation in…Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson’s disease uncontrolled by levodopa: final results of the PD MED LATER randomized clinical trial
Objective: PD MED LATER is a large, pragmatic trial aiming to determine which class of drug when added to levodopa provides the most effective control…Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicentre, parallel, randomised, double blind, phase 2b clinical trial
Objective: We aimed to assess whether clonidine, a specific α2-adrenergic receptor agonist, would improve impulse controls disorders (ICDs). Background: ICDs are frequently encountered in Parkinson’s…Evaluation of cases of psychosis from opicapone safety data
Objective: Investigate the likelihood of association of Opicapone (OPC) with psychotic symptoms (other than hallucinations). Background: Neuropsychiatric symptoms frequently occur in Parkinson’s Disease (PD) patients,…Clinical Improvement and drastic reduction of Equivalent Dose of Levodopa (LEDD) in an Advanced Parkinson’s Disease Patient after Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG) Treatment
Objective: Describe a patient in which after starting continuous infusion of LECIG a large reduction of the LEDD is achieved. Background: Gastroparesis (GP) is one…Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson’s disease treated with foslevodopa/foscarbidopa subcutaneous 24 hour infusion
Objective: To evaluate whether treatment with foslevodopa/foscarbidopa (LDP/CDP), a continuous (24‑hour/day) subcutaneous infusion of carbidopa/levodopa prodrugs, improves motor fluctuations and quality of life (QoL) in…Effect of the 5-HT2A/2C inverse agonist nelotanserin on dyskinesia in the MPTP-lesioned marmoset
Objective: To determine the effect of the serotonin 2A/2C (5-HT2A/2C) receptor inverse agonist nelotanserin on dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Background: Nelotanserin is a…What change to expect in duration of benefit per dose when switching from IR CD-LD to IPX203 (ER CD-LD)
Objective: To investigate if duration of benefit (“Good On” time) per dose during immediate-release (IR) carbidopa-levodopa (CD-LD) treatment predicts response to IPX203 conversion. Background: Levodopa’s…Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone
Objective: To identify genetic variants associated with different clinical responses in patients with Parkinson’s disease(PD) treated with opicapone. Background: Opicapone is a catechol‐O‐methyltransferase(COMT) inhibitor used…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 36
- Next Page »